New drug CR-001 enters human trials for Hard-to-Treat cancers

NCT ID NCT07335497

First seen Jan 17, 2026 · Last updated May 12, 2026 · Updated 14 times

Summary

This study tests a new drug, CR-001, in adults with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 290 people will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Study Site

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Clinical Study Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Clinical Study Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Clinical Study Site

    RECRUITING

    Dallas, Texas, 75230, United States

  • Clinical Study Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Clinical Study Site

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Clinical Study Site

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

  • Clinical Study Site

    RECRUITING

    Denver, Colorado, 80218, United States

  • Clinical Study Site

    RECRUITING

    Orlando, Florida, 32827, United States

  • Clinical Study Site

    RECRUITING

    Sarasota, Florida, 34236, United States

Conditions

Explore the condition pages connected to this study.